Skip to main content
. 2021 Jul 11;13(14):3467. doi: 10.3390/cancers13143467

Figure 1.

Figure 1

Exo70 is overexpressed in epithelial ovarian cancer (EOC) patients’ tissues and associated with shortened progression-free survival in platinum-treated EOC patients. (A) Representative photographs of immunohistochemistry (IHC) for Exo70 in normal ovarian and EOC tissues. Scale bar, 50 μm. (B) Statistics of Exo70 expression level in normal ovarian and EOC tissues. ** p < 0.01. (C) Representative photographs of immunohistochemistry for Exo70 in different pathological grades of EOC tissues. Scale bar, 50 μm. (D) Statistics of Exo70 expression level in different pathological grades of EOC tissues. Bonferroni correction was used to adjust p values. (E) Progression-free survival curve in platinum treated EOC patients of high versus low Exo70 expression. Data were generated online by using the Kaplan-Meier Plotter database based on microarray gene expression data from patients for whom PFS data are available (www.kmplot.com/ovarian (accessed on 3 February 2019)). (F) IHC staining of Exo70 in samples from platinum-sensitive (upper panel) and platinum-resistant (lower panel) EOC patients. Scale bar, 500 μm. (G) Statistics of Exo70 expression level in different pathological grades of EOC tissues. * p < 0.05.